India’s health system faces the ongoing challenge of responding to the needs of the most disadvantaged members of Indian society. New and advanced healthcare Products and their prices are two major concerns globally. Here comes in the picture, undoubtedly an ingenious company named Converge Biotech, a firm that is on step-up journey in improving access to healthcare through innovative techniques by aiming to provide quality and affordable drugs to the patients. As the prices of pharmaceuticals are major concerns in developed and developing countries, they directly affect the health expenses accounting for a large part of healthcare expenditure, thus, the diversity and concentration of the Converge team are apparent through their specialisations in global pharmaceutical and generic business and chronic therapy segments.
Converge Biotech believes in delivering innovative education programs and volunteering to meet the unmet needs of patients. This is how they follow up with their patients and shower. care for the society and strongly follow that the joy of business is not just earning profits but also equally taking the social responsibility to serve the society to the fullest. Converge Biotech is a leading healthcare company based at Hyderabad having a nationwide presence of being part of a USD 350 million group with a prominent presence in pharmaceutical with extended footprints in food processing and real estates.
The company started operation in 2015 and gradually moved to a PAN India presence with more than 200 Field strength. It has a strong foothold in the cardio-diabetic and critical care segment, with focus on providing high quality and affordable generic drugs to the patients. Converge Biotech aspires to become the change agent in the healthcare industry and the products offered by the company are produced in WHO GMP certified facilities and are audited by dedicated quality and pharmacovigilance team to ensure compliance to stringent quality measures. Subsequently, Converge Biotech’s key motive is to serve both the Doctors and Patients to leverage quality generics with an innovative dosage and packaging options in chronic segments. Converge believes in Equity in health and equity in health
care which is a longstanding guiding principle with the commitment to serve the needs of the patients significantly and improve their lives by providing quality and affordable generic drugs. In Converge’s consistent efforts to bring the best Healthcare solution they entered into a long-term strategic alliance with OncoDNA, a Belgium-based theranostic and genomic company specializing in precision oncology, to personalize care for late-stage cancer patients across India.
OncoDNA’s solutions are designed to guide oncologists with the aim of improving the clinical outcomes of patients living with advanced solid tumors such as breast or lung cancers, Converge Biotech will provide physicians and healthcare providers across India. Our foray into specialized diagnostic services in the oncology domain extends our vision of enabling medical community to make informed decisions and ensure better treatment outcomes. With this, we expect to bring in a ray of hope to a large number of cancer affected patients in India, whose treatment outcomes can be enhanced in light of accurate diagnosis.
Partha Roy Chowdhury, COO
They are also forefront in adopting innovative technologies when it comes to improve treatment outcomes such as available technologies for newer products for an example ‘STIR N SIP’, in which they introduce very well established ‘Alphacyclodextrin’ in soup form. Alphacyclodextrin is an established entity in absorbing fat from the meal and the other one is ‘LCTIN SHOT’ in which they have introduced L Carnitine 1gm in Nanotechnology, and currently this high dose is available in injectable form. Therefore, this innovation improves compliance among patients and clinicians. Converge Biotech, with their R&D team and Marketing & Sales team has strongly aligned their footprints to find out the problem areas in market research and their therapeutic gaps in order to provide a solution in the earliest possible time and simultaneously ensure reaching the innovation in the market and benefit the patients.
Converge Biotech believes In delivering innovative Education programs and Volunteering to meet the Unmet needs of patients
Converge Biotech has been awarded as a Fastest Growing company in 2017, Emerging Entrepreneur award in 2019 and Emerging Company of the Year 2020- 21 (Pharmaceutical) by Economic Times. And their placement in the Indian market is growing at a rapid pace from around revenue of more than Rs.1.50 lakh crore to the growth of 18 to 20 percent in next five years. That is the company anticipates a growth of 20-25 percent. This success is achieved with the help of the leadership team that is having deep understanding & expertise in the Healthcare Industry around the globe with great relationships with KOLs of India.
We use cookies to ensure you get the best experience on our website. Read more...
.jpg "Technology in Cancer Care: A story of evolving paradigms")
.jpg "Bringing Shop Floor to Manufacturer's palm: Smart Factory Solutions for tomorrow")
